Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML

Blood blood.2024026388.

https://doi.org/10.1182/blood.2024026388

Published: 2024

Includes: Supplemental data

Journal Articles

Preclinical Studies Demonstrating Efficacy of Tasquinimod in Models of Advanced Myeloproliferative Neoplasm (MPN) in Blastic Phase

Warren C. Fiskus, Lucia Masarova, Christopher Peter Mill, Christine Birdwell, Kaberi Das, John Davis, Hanxi Hou, Noor Alhamadani, Kevin Philip, Alicia Matthews, Taghi Manshouri, Tapan M. Kadia, Courtney D. DiNardo, Prithviraj Bose, Naveen Pemmaraju, Sanam Loghavi, Marie Törngren, Kapil N. Bhalla

Blood (2023) 142 (Supplement 1): 741.

https://doi.org/10.1182/blood-2023-185031

Published: 2023

Journal Articles

Actionable Findings from an Unbiased Drug Screen for Novel Single Agent and Combination Therapies Against AML with Mecom Re-Arrangement

Christine Birdwell, Warren C. Fiskus, Christopher Peter Mill, Tapan M. Kadia, Naval Daver, Courtney D. DiNardo, Koji Sasaki, John Davis, Kaberi Das, Hanxi Hou, Michele Ceribelli, Kapil N. Bhalla

Blood (2023) 142 (Supplement 1): 1419.

https://doi.org/10.1182/blood-2023-188371

Published: 2023

Journal Articles

Novel Agents with Efficacy Against Cellular Models of Familial Platelet Disorder with Myeloid Malignancy (FPD-MM) Associated with Germline Mutant RUNX1

Christopher Peter Mill, Warren C. Fiskus, Courtney D. DiNardo, Patrick K Reville, John Davis, Christine Birdwell, Kaberi Das, Hanxi Hou, Koichi Takahashi, Sanam Loghavi, Joseph D. Khoury, Kapil N. Bhalla

Blood (2023) 142 (Supplement 1): 2765.

https://doi.org/10.1182/blood-2023-190655

Published: 2023

Journal Articles

Pre-Clinical Efficacy of CDK7 Inhibitor-Based Combinations in Cellular Models of Advanced Myeloproliferative Neoplasms (MPN) Transformed to AML

Warren C. Fiskus, Prithviraj Bose, Lucia Masarova, Christopher Peter Mill, Christine Birdwell, John Davis, Kaberi Das, Hanxi Hou, Taghi Manshouri, Kevin Philip, Noor Alhamadani, Alicia Matthews, Sanam Loghavi, Kapil N. Bhalla

Blood (2023) 142 (Supplement 1): 1783.

https://doi.org/10.1182/blood-2023-185089

Published: 2023

Journal Articles

Notable Efficacy of Co-Treatment with FHD-286, a Dual BRG1/BRM ATP-Ase Inhibitor, and Menin or BET Inhibitor, Decitabine or Venetoclax Against AML with MLL-r or Mutant NPM1

Warren C. Fiskus, Jessica Piel, Murphy Hentemann, Christopher Peter Mill, Christine Birdwell, Kaberi Das, John Davis, Hanxi Hou, Noor Alhamadani, Kevin Philip, Alicia Matthews, Tapan M. Kadia, Naval Daver, Sanam Loghavi, Branko Cuglievan, Courtney D. DiNardo, Kapil N. Bhalla

Blood (2023) 142 (Supplement 1): 4160.

https://doi.org/10.1182/blood-2023-182575

Published: 2023

Journal Articles

Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2

Christopher P. Mill, Warren Fiskus, Courtney D. DiNardo, Christine Birdwell, John A. Davis, Tapan M. Kadia, Koichi Takahashi, Nicholas Short, Naval Daver, Maro Ohanian, Gautam Borthakur, Steven M. Kornblau, Michael R. Green, Yuan Qi, Xiaoping Su, Joseph D. Khoury, Kapil N. Bhalla

Blood (2022) 139 (6): 907–921.

https://doi.org/10.1182/blood.2021013156

Published: 2022

Includes: Supplemental data

Journal Articles

Clinical-Stage Menin Inhibitor KO-539 Is Synergistically Active with Multiple Classes of Targeted Agents in KMT2A-r and NPM1-Mutant AML Models

John A. Davis, Warren C. Fiskus, Naval Daver, Christopher Peter Mill, Christine Birdwell, Arnold Salazar, Kevin Philip, Tapan M. Kadia, Courtney D. DiNardo, Mollie Leoni, Francis Burrows, Kapil N. Bhalla

Blood (2021) 138 (Supplement 1): 3357.

https://doi.org/10.1182/blood-2021-149831

Published: 2021

Journal Articles

Pre-Clinical Efficacy of Targeting TBL1/R-β-Catenin-TCF7L2 Axis Against AML with 3q26 Lesions and EVI1 Overexpression

Christine Birdwell, Warren C. Fiskus, Christopher Peter Mill, John A. Davis, Arnold Salazar, Courtney D. DiNardo, Koichi Takahashi, Steve Horrigan, Tapan M. Kadia, Kapil N. Bhalla

Blood (2021) 138 (Supplement 1): 3349.

https://doi.org/10.1182/blood-2021-154285

Published: 2021

Journal Articles

Preclinically Effective Menin Inhibitor SNDX-50469 and SNDX-5613-Based Combinations Against MLL1-Rearranged (MLL-r) or NPM1-Mutant AML Models

Warren C. Fiskus, Christopher Peter Mill, Christine Birdwell, John A. Davis, Arnold Salazar, Kevin Philip, Tapan M. Kadia, Courtney D. DiNardo, Koichi Takahashi, Gerard M. McGeehan, Naval Daver, Kapil N. Bhalla

Blood (2021) 138 (Supplement 1): 3340.

https://doi.org/10.1182/blood-2021-152060

Published: 2021

Journal Articles

Homoharringtonine and Mebendazole Are Preferentially Lethal Against Models of Myeloid Malignancy Associated with Germline Mutant RUNX1

Christopher Peter Mill, Warren C. Fiskus, Courtney D. DiNardo, Christine Birdwell, Arnold Salazar, Arnold Salazar, John A. Davis, Koichi Takahashi, Joseph D. Khoury, Kapil N. Bhalla

Blood (2021) 138 (Supplement 1): 1177.

https://doi.org/10.1182/blood-2021-152871

Published: 2021

Journal Articles

Preclinical Efficacy of a Novel Omacetaxine-Based Therapy for AML Expressing Somatic or Germline Mutant RUNX1

Christopher Peter Mill, PhD BA, Warren Fiskus, BSc,PhD, Courtney D. DiNardo, MD MSCE, Christine Birdwell, Bernardo H Lara, Joseph D. Khoury, MD, Kapil N. Bhalla, MD

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-141742

Published: 2020

Journal Articles

Pre-Clinical Efficacy of Co-Targeting GFI1/KDM1A and BRD4 or JAK1/2 Against AML and Post-MPN Secondary AML Blast Progenitor Cells

Warren Fiskus, BSc,PhD, Christopher Peter Mill, PhD BA, Christine Birdwell, Bernardo H Lara, Prithviraj Bose, MD, Lucia Masarova, MD, Tapan M. Kadia, MD, Joseph D. Khoury, MD, Taghi Manshouri, PhD, Srdan Verstovsek, MD PhD, Kapil N. Bhalla, MD

Blood (2020) 136 (Supplement 1): 27.

https://doi.org/10.1182/blood-2020-140212

Published: 2020

Journal Articles

BET Protein Antagonist-Based Therapy of Novel Models of Richter Transformation-Diffuse Large B-Cell Lymphoma (RT-DLBCL)

Warren Fiskus, BSc,PhD, Christopher Peter Mill, PhD BA, Bernardo H Lara, Christine Birdwell, Michael R Green, PhD, Joseph D. Khoury, MD, Kapil N. Bhalla, MD

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-138637

Published: 2020

NARROW

Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML

Preclinical Studies Demonstrating Efficacy of Tasquinimod in Models of Advanced Myeloproliferative Neoplasm (MPN) in Blastic Phase

Actionable Findings from an Unbiased Drug Screen for Novel Single Agent and Combination Therapies Against AML with Mecom Re-Arrangement

Novel Agents with Efficacy Against Cellular Models of Familial Platelet Disorder with Myeloid Malignancy (FPD-MM) Associated with Germline Mutant RUNX1

Pre-Clinical Efficacy of CDK7 Inhibitor-Based Combinations in Cellular Models of Advanced Myeloproliferative Neoplasms (MPN) Transformed to AML

Notable Efficacy of Co-Treatment with FHD-286, a Dual BRG1/BRM ATP-Ase Inhibitor, and Menin or BET Inhibitor, Decitabine or Venetoclax Against AML with MLL-r or Mutant NPM1

Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2

Clinical-Stage Menin Inhibitor KO-539 Is Synergistically Active with Multiple Classes of Targeted Agents in KMT2A-r and NPM1-Mutant AML Models

Pre-Clinical Efficacy of Targeting TBL1/R-β-Catenin-TCF7L2 Axis Against AML with 3q26 Lesions and EVI1 Overexpression

Preclinically Effective Menin Inhibitor SNDX-50469 and SNDX-5613-Based Combinations Against MLL1-Rearranged (MLL-r) or NPM1-Mutant AML Models

Homoharringtonine and Mebendazole Are Preferentially Lethal Against Models of Myeloid Malignancy Associated with Germline Mutant RUNX1

Preclinical Efficacy of a Novel Omacetaxine-Based Therapy for AML Expressing Somatic or Germline Mutant RUNX1

Pre-Clinical Efficacy of Co-Targeting GFI1/KDM1A and BRD4 or JAK1/2 Against AML and Post-MPN Secondary AML Blast Progenitor Cells

BET Protein Antagonist-Based Therapy of Novel Models of Richter Transformation-Diffuse Large B-Cell Lymphoma (RT-DLBCL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only